Blocking Complement Factor B Halts Pancreatic Cancer Growth

A study published in The American Journal of Pathology found that blocking complement factor B slowed pancreatic cancer cell growth and shrank tumors in mice.

Updated on Nov. 10, 2026 in Cancer

Isometric editorial illustration of unlabeled glass vials and stacked petri dishes on a laboratory bench in muted slate, cream, and teal, suggesting cancer research.
Researchers at Chiba University found that blocking complement factor B with iptacopan slowed pancreatic cancer cell growth and shrank tumors in mice. AI Illustration. Upload story photo >

Live Poll

Do you think new cancer treatments are making a real difference for patients?

Researchers at Chiba University in Japan found that blocking complement factor B with iptacopan reduced pancreatic cancer cell proliferation and promoted cellular senescence. The findings were published in The American Journal of Pathology on November 9, 2026.

Why it matters

Pancreatic ductal adenocarcinoma has a five-year survival rate below 15%, making new treatment approaches urgently needed. High complement factor B levels in tumor-surrounding tissue were linked to poorer survival and more frequent recurrence.

The findings come from preclinical cell and mouse model experiments alongside analysis of human pancreatic tumor tissue, with pancreatic ductal adenocarcinoma's five-year survival rate below 15%. Whether iptacopan's effects carry over to human patients remains unknown, as clinical testing has not been reported.

The players

Chiba University

A national university in Chiba, Japan, whose Graduate School of Medicine conducted the research on complement factor B and pancreatic cancer.

Iptacopan

An approved oral complement factor B inhibitor developed for certain rare complement-mediated diseases, now studied for its potential anticancer effects.

The details

Researchers examined complement factor B levels in human pancreatic tumor tissue and tested the selective inhibitor iptacopan in cancer cells and a mouse model. Blockade reduced cell proliferation, increased p21 expression, and lowered regulatory T cells while increasing CD8+ T-cell infiltration within tumors.

Timeline

  1. November 9, 2026: Study published in The American Journal of Pathology.

Health Landscape

The study builds on earlier research showing complement factor B is upregulated during pancreatic ductal adenocarcinoma development. It moves that observation toward a potential therapy by testing whether an approved drug for rare complement-mediated diseases can slow tumor growth.

The results remain preclinical, so iptacopan is not yet available as a pancreatic cancer treatment. Patients and caregivers should discuss any emerging therapies with their oncologists as human trials, if pursued, develop.

The takeaway

Blocking complement factor B may offer a new angle against pancreatic cancer, which has historically had poor survival outcomes. Combining such approaches with chemotherapy and immunotherapy is a direction researchers will need to test carefully.

Further reading

Explore more on Cancer research and treatment developments.

More information

Read the full published study on complement factor B blockade in pancreatic cancer00257-9/fulltext) in The American Journal of Pathology.

Source note: This article includes information reported by News-Medical.

Live Poll

Do you think new cancer treatments are making a real difference for patients?